Poor outcome associated with elevated ACSS2 expression has been reported in human triple-negative breast cancers, glioblastoma and brain metastases, non-small-cell lung carcinoma, cervical squamous cell carcinoma [47, 48, 60, 61], and in concordance, we similarly uncovered a poor outcome AML subtype featuring ACSS1/ACSS2-high, associated with TP53 mutations, and an enrichment of mitochondrion genes indicating a causal role for ACSS1/ACSS2. Here, ACSS2 is linked to triple-negative breast carcinoma.